Spelling suggestions: "subject:"retainrelease"" "subject:"sustainedrise""
31 |
Systèmes injectables biodégradables pour la libération prolongée d'ivermectine / Injectable biodegradable systems for ivermectine sustained releaseCamargo-Pardo, Javier-Andrés 05 November 2010 (has links)
Des systèmes injectables de formation in situ ont été utilisés dans les dernières années pour l'obtention de formulations de préparation facile et permettant la libération prolongée de principes actifs. Ces systèmes utilisant des solvants biocompatibles et des polymères biodégradables sont des liquides (solutions ou émulsions) qui une fois injectés dans l'organisme donnent lieu à des implants (ISI) ou à des microparticules (ISM) solides. La formation de ces systèmes est induite par la précipitation du polymère à partir des solutions polymériques qu'ils contiennent lors du contact avec les fluides corporaux aqueux. Dans ce travail, des ISI et des ISM, réalisés à partir des polymères de l'acide lactique et/ou glycolique (PLA et PLGA) et des différents solvants biocompatibles, pour la libération prolongée d?ivermectine (IVM), un principe actif antiparasitaire faiblement biodisponible par la voie orale, ont été développés. Les profils de libération du principe actif in vitro et in vivo à partir de ces systèmes, ont été comparés avec ceux obtenus à partir de microparticules réalisées par la méthode classique dite d'émulsion simple - évaporation de solvant ; il s'agit d'une technique aux multiples étapes, à coût élevé et dont l'utilisation de solvants toxiques la font difficilement industrialisable. La libération du principe actif à partir des microparticules obtenues par émulsion simple/évaporation du solvant a été influencée par la forte interaction du principe actif avec les polymères mais aussi par la porosité. Dans le cas des systèmes in situ, la vitesse de libération d'IVM a été conditionnée par la solubilité dans l'eau du solvant biocompatible sélectionné et par les interactions solvant/polymère. Pour les ISM, des paramètres tels que la nature de la phase externe, aqueuse (ISM-O/W) ou huileuse (ISM-O/O), la solubilité dans l'eau du solvant de la phase interne, l'affinité entre les phases et l'affinité de l'IVM pour chacune des phases, ont déterminé la vitesse de libération du principe actif. La bonne stabilité ainsi que les profils de libération plus prolongés et présentant une faible libération initiale du principe actif in vivo et in vitro, ont montré que les ISI et les ISM réalisés à partir de solvants biocompatibles de faible solubilité dans l'eau tels que la triacetine sont les plus indiqués pour l'encapsulation d'IVM par rapport à ceux plus solubles dans l'eau comme la N-methyl-2-pyrrolidone et la 2-pyrrolidone. Ces systèmes représentent donc une alternative intéressante par rapport aux formulations conventionnelles d'IVM / In situ forming injectable systems have been used in the past years to obtain sustained drug release formulations which are easy to prepare. These systems using biocompatible solvents and biodegradable polymers are liquids (solutions or emulsions) that upon injection on the body lead to solid implants (ISI) or microparticles (ISM). These systems are formed in contact with water body fluids by polymer precipitation from the polymeric solution. In this work, ISI and ISM made from lactide and/or glycolide polymers (PLA and PLGA) and different biocompatible solvents were performed to obtain sustained release of ivermectin (IVM), an antiparasitic drug with a low oral bioavailability. In vitro and in vivo drug release profiles from these systems were compared with those from microparticles obtained by the classical simple emulsion/solvent evaporation method, which is difficult to propose in industry because of its multiple steps, high cost and the solvent toxicity. Drug release from simple emulsion/solvent evaporation microparticles was affected by the strong polymer/drug interactions and porosity. Concerning to in situ forming systems, the rate of IVM release was dependent on solvent water solubility and solvent/polymer interactions. The nature of the external phase, water (ISM-O/W) or oil (ISM-O/O), the water solubility of the solvent in the internal phase, phase affinity and IVM/phase affinity determined drug release from ISM. The good stability, the in vitro and in vivo sustained release and the low burst effect of IVM, indicated that ISI and ISM formulated from low hydrosoluble biocompatible solvents such as triacetin are more appropriated to IVM formulation instead of those based on more hydrophilic solvent (N-methyl-2-pyrrolidone and 2-pyrrolidone). These systems are an interesting alternative to conventional IVM formulations
|
32 |
Desenvolvimento, caracterização e avaliação de sistemas microestruturados para veiculação de ácido retinóico na pele / Development, characterization and evaluation of microparticulate systems for skin delivery of retinoic acidAna Amélia Moreira Lira 27 March 2007 (has links)
Este trabalho propôe o desenvolvimento de micropartículas para veiculação deste fármaco na pele, aumentando a estabilidade da molécula e proporcionando uma liberação sustentada, o que resulta na otimização da terapia, visto que ocorre a redução dos efeitos colaterais. As micropartículas foram produzidas por três métodos diferentes, os dois primeiros utilizando a quitosana como polímero e o último utilizando uma associação de alginato com quitosana. As micropartículas de quitosana resultaram em interação do fármaco veiculado com o polímero e desta forma a sua utilização como sistema de liberação para veiculação do fármaco estudado foi descartada. As micropartículas de alginato/quitosana encapsularam efetivamente o fármaco, resultando em partículas irregulares com diâmetro médio de 148m. Elas apresentaram liberação sustentada do ácido retinóico por um período compatível com sua utilização tópica e por isso, parecem ser adequados para garantir estabilidade ao fármaco. Além disso, elas diminuíram a retenção do fármaco no estrato córneo quando comparado ao fármaco livre, mantendo seus níveis nas outras camadas mais profundas da pele. Esse direcionamento sítio-específico poderia diminuir a sua irritação dérmica, possibilitando, dessa forma, juntamente com o aumento de sua estabilidade, a obtenção de efeitos terapêuticos com a utilização de doses menores. Também não foram observadas interações entre o fármaco e o polímero demonstrando que a matriz de alginato foi capaz de proteger o fármaco do contato e da interação com a quitosana. Além disso, o método utilizado mostrou ser simples e rápido, realizado em condições amenas, sem o inconveniente da utilização de agentes cross-linking químicos tóxicos, como o glutaraldeído. / This study proposes the development of microparticles for drug delivery into the skin, thus increasing molecule stability and providing sustained release that results in therapy optimization as a result of reduction in side-effects. The microparticles were produced by three different methods. The two first methods used chitosan as a polymer, and the third utilized a chitosanalginate association. The chitosan microparticles resulted in the interaction of the delivered drug with the polymer; hence, its use as a release system for delivery of the studied drug was disregarded. The alginate/chitosan microparticles effectively encapsulated the drug, resulting in irregular particles with a mean diameter of 148m. They exhibited sustained release of retinoic acid for a period of time that was compatible with topical application and, therefore, seem to be suitable to ensure drug stability. Additionally, the microparticles decreased drug retention in the stratum corneum as compared to the free drug, thus keeping its levels in other deeper layers of the skin. Such site-specific direction could reduce dermal irritation, consequently enabling, conjointly with stability increase, the achievement of therapeutic effects with the use of smaller doses. Drug-polymer interactions were also not observed, showing that the alginate matrix was capable of protecting the drug from the contact and interaction with chitosan. Besides, the applied method proved to be simple and fast. It can be performed in mild conditions without the inconvenience of using toxic cross-linking chemical agents, such as glutaraldehyde.
|
33 |
Desenvolvimento, caracterização e avaliação de sistemas microestruturados para veiculação de ácido retinóico na pele / Development, characterization and evaluation of microparticulate systems for skin delivery of retinoic acidLira, Ana Amélia Moreira 27 March 2007 (has links)
Este trabalho propôe o desenvolvimento de micropartículas para veiculação deste fármaco na pele, aumentando a estabilidade da molécula e proporcionando uma liberação sustentada, o que resulta na otimização da terapia, visto que ocorre a redução dos efeitos colaterais. As micropartículas foram produzidas por três métodos diferentes, os dois primeiros utilizando a quitosana como polímero e o último utilizando uma associação de alginato com quitosana. As micropartículas de quitosana resultaram em interação do fármaco veiculado com o polímero e desta forma a sua utilização como sistema de liberação para veiculação do fármaco estudado foi descartada. As micropartículas de alginato/quitosana encapsularam efetivamente o fármaco, resultando em partículas irregulares com diâmetro médio de 148m. Elas apresentaram liberação sustentada do ácido retinóico por um período compatível com sua utilização tópica e por isso, parecem ser adequados para garantir estabilidade ao fármaco. Além disso, elas diminuíram a retenção do fármaco no estrato córneo quando comparado ao fármaco livre, mantendo seus níveis nas outras camadas mais profundas da pele. Esse direcionamento sítio-específico poderia diminuir a sua irritação dérmica, possibilitando, dessa forma, juntamente com o aumento de sua estabilidade, a obtenção de efeitos terapêuticos com a utilização de doses menores. Também não foram observadas interações entre o fármaco e o polímero demonstrando que a matriz de alginato foi capaz de proteger o fármaco do contato e da interação com a quitosana. Além disso, o método utilizado mostrou ser simples e rápido, realizado em condições amenas, sem o inconveniente da utilização de agentes cross-linking químicos tóxicos, como o glutaraldeído. / This study proposes the development of microparticles for drug delivery into the skin, thus increasing molecule stability and providing sustained release that results in therapy optimization as a result of reduction in side-effects. The microparticles were produced by three different methods. The two first methods used chitosan as a polymer, and the third utilized a chitosanalginate association. The chitosan microparticles resulted in the interaction of the delivered drug with the polymer; hence, its use as a release system for delivery of the studied drug was disregarded. The alginate/chitosan microparticles effectively encapsulated the drug, resulting in irregular particles with a mean diameter of 148m. They exhibited sustained release of retinoic acid for a period of time that was compatible with topical application and, therefore, seem to be suitable to ensure drug stability. Additionally, the microparticles decreased drug retention in the stratum corneum as compared to the free drug, thus keeping its levels in other deeper layers of the skin. Such site-specific direction could reduce dermal irritation, consequently enabling, conjointly with stability increase, the achievement of therapeutic effects with the use of smaller doses. Drug-polymer interactions were also not observed, showing that the alginate matrix was capable of protecting the drug from the contact and interaction with chitosan. Besides, the applied method proved to be simple and fast. It can be performed in mild conditions without the inconvenience of using toxic cross-linking chemical agents, such as glutaraldehyde.
|
34 |
Desenvolvimento de comprimidos de liberação prolongada de nimesulida contendo ferrita para avaliação do trânsito gastrintestinal por meio de técnica biomagnética / Development of prolonged release tablets of nimesulide containing ferrite for evaluation of gastrointestinal transit by means of biomagnetic technique.Ruberlan de Oliveira Santos 13 April 2018 (has links)
As Formas Farmacêuticas de Liberação Prolongada (FFLP) têm sido uma alternativa eficaz na terapia, pois proporcionam maior adesão do paciente ao tratamento em função da redução da frequência de dosagem ao longo do dia, sendo sua principal característica, a modulação da liberação/dissolução do fármaco. Entretanto, esta etapa pode ser influenciada por diferentes fatores, dentre eles: os físico-químicos relacionados ao fármaco; os farmacêuticos, principalmente relacionados aos excipientes empregados e às técnicas de obtenção da forma farmacêutica (FF) e os fisiológicos do trato gastrintestinal (TGI), como por exemplo, o pH dos líquidos do TGI, o tempo de esvaziamento gástrico, a motilidade intestinal, entre outros. Desse modo, a avaliação do trânsito da FF no TGI, após a sua administração, permite uma melhor compreensão dos fatores que podem afetar as etapas de liberação/dissolução do fármaco in vivo. Dentre as técnicas empregadas com esse objetivo, destacam-se: a cintilografia e os métodos biomagnéticos. A Biosusceptometria de Corrente Alternada (BAC) é um método biomagnético que tem se mostrado promissor para este tipo de estudo, por ser não invasivo, portátil, livre de radiação ionizante, e por apresentar acurácia e versatilidade. Diante do exposto, o presente trabalho teve como objetivos, desenvolver e caracterizar sob o aspecto biofarmacotécnico in vitro, um sistema de liberação prolongada contendo nimesulida (fármaco-modelo) e marcador magnético (ferrita), visando obtenção de ferramenta para avaliação do trânsito gastrintestinal por meio de técnica biomagnética. Para isto foram desenvolvidas quatro formulações de comprimidos de liberação prolongada contendo nimesulida, ferrita e diferentes concentrações de hidroxipropilmetilcelulose (HPMC): NF1 (30% HPMC); NF2 (23% HPMC); NF3 (17% HPMC) e NF4 (10% HPMC). Essas foram avaliadas quanto ao comportamento de dissolução por meio de ensaios com aparato 4 e avaliação da cinética e da eficiência de dissolução (ED%). Posteriormente, estudos biomagnéticos, in vitro e in vivo, foram conduzidos com emprego da técnica de BAC para a formulação selecionada. Os resultados obtidos mostraram que as 04 formulações desenvolvidas apresentaram porcentagens de dissolução distintas em função das diferentes concentrações de HPMC (NF1 = 13,2%; NF2 = 40,1%; NF3 = 72,5% e NF4 = 91,5%). A formulação NF4, com menor concentração de HPMC, foi escolhida para os estudos por meio de BAC em função dos resultados de ED% (54,3%) e por apresentar comportamento mais próximo de uma formulação de liberação prolongada. Em relação aos resultados de BAC in vitro, destaca-se que a formulação NF4 (10%HPMC) apresentou aumento de área magnética de forma independente do pH do meio, sugerindo que a hidratação/intumescimento da HPMC independe do pH. Em relação à avaliação do trânsito intestinal (estudo in vivo) foram obtidos os seguintes dados: Tempo médio de Residência Gástrica (TTR) - 89 minutos; Tempo médio do Trânsito Orocecal (TTO) - 313 minutos e Tempo médio do Trânsito Intestinal (TTI) - 224 minutos. Os dados de BAC in vivo permitiram observar que o aumento de área magnética atingiu um platô em cerca de 80 minutos após a administração da formulação NF4. A comparação dos dados de BAC in vitro e BAC in vivo, relacionados ao trânsito gastrintestinal, indica que a formulação NF4, após apresentar o ápice de intumescimento, foi capaz de manter sua estrutura permanente ao longo do TGI, favorecendo assim a liberação modulada do fármaco. Os resultados obtidos demonstraram que a formulação desenvolvida foi eficiente para avaliar e caracterizar o trânsito no TGI por meio da técnica de BAC e também permitiram uma estimativa do comportamento do fármaco em relação a solubilidade em cada porção do TGI, proporcionando assim uma ferramenta adequada para avaliação do trânsito do TGI e desenvolvimento de FFLP. / Extended Release (ER) dosage forms have been an effective alternative in therapy, since they provide greater patient adherence to treatment as a function of the reduction of the frequency of dosing throughout the day, its main characteristic being the release / dissolution modulation of the drug. However, this stage can be influenced by different factors, among them: the physical and chemical related to the drug; the pharmacists, mainly related to the excipients employed and the techniques of obtaining the form dosage and the physiological ones of the gastrointestinal tract (GI tract), as for example, the pH of the liquid of the GI tract, gastric emptying time, intestinal motility, among others. Thus, assessment of dosage forms transit in GI tract after its administration allows a better understanding of the factors that may affect the drug release / dissolution steps in vivo. Among the techniques used for this purpose, the following stand out: scintigraphy and biomagnetic methods. Alternating Current Biosensiometry (ACB) is a biomagnetic method that has shown promise for this type of study, since it is non-invasive, portable, free of ionizing radiation, and because of its accuracy and versatility. In view of the above, the aim of this work was to develop and characterize a sustained release system containing nimesulide (study drug) and magnetic marker (ferrite) under the in vitro biopharmaceutical aspect, aiming to obtain a tool to evaluate the GI tract transit through means of biomagnetic technique. For this, four formulations of extended release tablets containing nimesulide, ferrite and different concentrations of hydroxypropylmethylcellulose (HPMC): NF1 (30% HPMC) were developed; NF2 (23% HPMC); NF3 (17% HPMC) and NF4 (10% HPMC). These were evaluated for dissolution behavior by apparatus 4, assays and kinetics and dissolution efficiency (ED%). Subsequently, biomagnetic studies, in vitro and in vivo, were conducted using the ACB technique for the selected formulation. The results showed that the formulations developed showed different percentages of dissolution as a function of the different concentrations of HPMC (NF1 = 13.2%, NF2 = 40.1%, NF3 = 72.5% and NF4 = 91.5%). The NF4 formulation, with a lower concentration of HPMC, was chosen for the ACB studies as a function of ED% results (54,3%) and because of the behavior of a sustained release formulation. In relation to the in vitro ACB results, the NF4 formulation (10% HPMC) showed an increase in magnetic area independently of the pH of the medium, suggesting that the HPMC hydration / swelling is independent of pH. In relation to intestinal transit evaluation (in vivo study) the following data were obtained: Mean Time of Gastric Residency (TTR) - 89 minutes; Mean Time of Orocecal Transit (OCTT) - 313 minutes and Mean Time of lntestinal Transit (TTI) - 224 minutes. ACB data in vivo showed that the increase in magnetic area reached a plateau in about 80 minutes after administration of the NF4 formulation. Comparison of in vitro ACB and ACB data in vivo, related to gastrointestinal transit, indicates that the NF4 formulation, after showing the swelling apex, was able to maintain its permanent structure throughout the GI tract, thus favoring the modulated release of the drug. The obtained results demonstrated that the developed formulation was efficient to evaluate and characterize the transit in the GI tract by means of the ACB technique and allowed a prediction of the behavior of the drug in relation to the solubility in each portion of the GI tract, thus providing a suitable tool for evaluation of the GI tract transit and the development of sustained release formulation.
|
35 |
Desenvolvimento de microemulsões e sua transformação in situ em géis de fase líquido-cristalina como plataforma para liberação sustentada de fármacos e seu uso no tratamento do alcoolismo. / Development of microemulsions and their in situ transformation in liquid-crystalline phase gels as a platform for sustained release of drugs and their use in the treatment of alcoholism.Santos, Rogério Aparecido dos 06 December 2017 (has links)
Este estudo visa o desenvolvimento de microemulsões que, após captação de água do tecido subcutâneo, transformar-se-ão em gel nanoestruturado de fase hexagonal para liberação sustentada de naltrexona e tratamento do alcoolismo. A microemulsão selecionada, composta por monooleína, tricaprilina, propilenoglicol e água (ME-MO) resultou na liberação in vitro de 31 % de naltrexona em 96 h. Após sua administração subcutânea, foi observada formação do gel em 48 h, o qual persistiu por mais de 30 dias in vivo, promovendo liberação prolongada do marcador fluorescente Alexa flúor. A eficácia da formulação foi avaliada em modelo de preferência condicionada por lugar induzida por etanol; ME-MO com 5 e 10% de naltrexona foi comparada à solução de naltrexona diária. Não observou-se diferença significativa entre a solução de naltrexona e ME-MO 5%, enquanto que ME-MO 10% diferiu destas, e antagonizou a preferência condicionada por lugar. Esses resultados demonstram o potencial de ME-MO como uma plataforma para liberação prolongada de fármacos no tratamento de dependência química. / This study focuses on the development of microemulsions that after in vivo water uptake of the subcutaneous tissue will turn into liquid-crystalline gels for sustained release of naltrexone, used in the treatment of alcoholism. Three microemulsions based on monoolein and tricapryline (ME-MO), vitamin E TPGS and propylene glycol, TPGS and Span were selected. The latter resulted is faster drug release (65% in 96 h). Based on the ability of the gel formed to withstand dilution, ME-MO was selected for in vivo studies. After subcutaneous administration, hexagonal phase formation was observed in 48 h and its persistence for more than 30 days in those animals. The efficacy of the formulation was assessed using conditioned preference place model. The animals were divided into four groups: Saline (control); Naltrexone solution (1 mg / kg) daily for 8 days (30 min before ethanol administration), and ME-MO with 5% or 10% naltrexone (single administration). The results suggest that ME-MO 10% antagonized the preference induced by ethanol.
|
36 |
Development of an Intraruminal Controlled-Release DeviceMcLellan, Bradley John January 2007 (has links)
Slow-release devices retained in the rumen, are a simple method for continuous administration of bioactives to ruminant animals. To satisfy regulatory requirements and avoid waste of bioactive due to under- or over-dosing, it is advantageous to have a constant and predictable release rate. Existing intraruminal controlled-release technologies cannot easily be adapted for different bioactives or rates of release and can be influenced by the variable physiological environment in the rumen. Some existing commercial products use the pressure generated by a hydrogen gas-producing cell to extrude fluids from a syringe-like device. This technology may provide advantages for ruminal controlled-release as the gas production rate is unaffected by environment in the rumen and can be easily adjusted using electrical resistance applied to the gas cell. This technology was adapted for use in the rumen in these studies. Initial experiments identified the need for greater understanding of the rate that hydrogen is produced by the gas cell and the rate that gas diffuses through the barrel walls. Gas production rate was found to be inversely proportional to the resistance applied to the gas-producing cell. Factors affecting gas diffusion rate from the device were studied and a polymer was identified that reduced hydrogen diffusion to 5% of that for the initial components used. A relationship was developed to predict the release profile of a device. Controlled-release devices were constructed from selected materials. They released blank formulation at in vitro at a constant rate, which was within experimental variation of predicted values. Release rates from the devices used in vivo were slightly higher than predicted. The presence of rumen gases inside in vivo devices suggested that the difference may be due to inward diffusion of these gases; these may be eliminated by further study of barrel materials. Recommendations on the redesign of this technology for use as a generic intraruminal delivery system are given.
|
37 |
Investigation of Polymeric Composites for Controlled Drug ReleaseYeh, Hsi-wei 01 January 2017 (has links)
The Electrospray (ES) technique is a promising particle generation method for drug delivery due to its capabilities of producing monodisperse PLGA composite particles with unique configurations and high drug encapsulation efficiency. In the dissertation work, the coaxial dual capillary ES was used to generate drug-loaded core-shell PLGA particles to study the effects of particle filling materials, drug loading locations and particle shell thicknesses on the resultant in vitro release behaviors of the hydrophilic and/ or hydrophobic model drugs. Through release profile characterization of drug-loaded PLGA particles (particle size: 400 nm and 1 μm), it was confirmed that the co-encapsulation of Budesonide (BUD, the hydrophobic small-molecule model drug) and Theophylline (THY, the hydrophilic small-molecule model drug) in the particle cores is the most effective drug loading strategy for extended release of the fixed combined BUD and THY. Particles composed of PLGA fillers with lower molecular weights and with greater shell layer thicknesses could release THY in a well controlled fashion. On the other hand, a slower release rate of Bovine Serum Albumin (BSA, the protein model drug) from PLGA particles with greater shell thickness was also observed. Sequential release of BSA and Paclitaxel (PTX, the hydrophobic small-molecule anti-cancer model drug) was achieved by the 400-nm PLGA (Mw: 7,000-17,000 g/mol, LA/GA: 50/50) particles with potential biopharmaceutical applications in cancer therapy.
|
38 |
PEO hot melt extrudates for controlled drug delivery / Extrudats à base d'oxyde de poly éthylène pour la libération contrôléeCantin, Oriane 16 December 2016 (has links)
Parmi les procédés de fabrication continue, l’extrusion par fusion à chaud est une technique dont l’intérêt dans le domaine pharmaceutique est grandissant. Ce procédé permet la formation des dispersions solides des substances actives au sein des matrices polymériques ou lipidiques. En fonction de l’excipient et de la substance active, cela peut être largement utilisé pour la conception des systèmes: (i) pour une libération immédiate, (ii) pour une libération modifiée et (iii) pour le masquage de goût. Les systèmes à libération modifiée sont des dispositifs intéressants qui permettent d’améliorer la biodisponibilité de la substance active, son efficacité ainsi que l’observance des patients. En fonction de la nature de l’excipient, différents systèmes avec des mécanismes de libération variés peuvent être produit, notamment des matrices inerte, érodable ou gonflante. Le poly éthylène oxide est un polymère semi- cristallin et hydrophile qui peut être utilisé pour la libération contrôlée. Son point de fusion compris entre 63 et 67 °C le rend adapté pour l’extrusion. Surtout, ses capacités de gonflement permettent d’administrer la substance active de façon contrôlée en fonction du poids moléculaire du poly éthylène oxide. Les objectifs de ce travail sont (i) d’étudier l’impact des paramètres critiques du procédé (température d’extrusion et vitesse des vis d’extrudeuse) sur le profil de libération de la substance active, (ii) de déterminer l’impact des paramètres de formulations (poids moléculaire du poly éthylène oxide, charge et type de la substance active) sur le profil de libération de la substance active et (iii) d’évaluer des formes galéniques solides conçues par le procédé d’extrusion à celui de la compression directe. Il a été montré que la variation de la température d’extrusion et de la vitesse des vis altérait l’apparence de l’extrudat et ainsi la distribution de la substance active au sein de l’extrudat. Il s’est avéré dans notre étude que la libération de la substance active n’était pas particulièrement affectée par ces changements de température et vitesse de vis de l’extrudeuse. De plus, cette étude a permis de fixer les paramètres pour les projets suivants: température 100 °C ; vitesse des vis 30 rpm ; longueur de la forme galénique 1 cm. Des extrudats de poly ethylène oxide contenant 10 % de théophylline et du poly éthylène oxide de 100 à 7000 kDa ont été utilisés dans ce travail. Il a été observé que lorsque le poids moléculaire du poly ethylène oxide augmente de 100 à 600 kDa, la libération en substance active diminue de façon importante alors qu’une augmentation jusqu’à 7000 kDa ne diminue que légèrement la libération. Des études du gonflement ont montré que ce phénomène corrélait aux variations de volume de la partie opaque de l’extrudat (gel non transparent et cœur solide). / Among continuous manufacturing processes, hot melt extrusion is a technique with growing interest in the pharmaceutical field. This process enables the formation of solid dispersions of many drugs within a polymeric or lipidic carrier. Hot melt extrusion can be widely used for different issues using the appropriate carrier and drug. Here are the mostly used concepts in pharmaceutical solid dosage forms: (i) immediate release, (ii) modified release and (iii) taste masking. Modified release systems have been taken into account to be very interesting devices for the improvement of drug- bioavailability, drug- efficacy as well as the patient compliance. Various systems with different release mechanisms can be manufactured, depending on the nature of the carrier (inert, erodible, and swelling matrices). Poly ethylene oxide is a semi crystalline and hydrophilic polymer which can be used to control drug delivery. The poly ethylene oxide melting point ranging from 63 to 67 °C makes it suitable for hot melt extrusion. Importantly, the swelling capacities of the hydrophilic poly ethylene oxide matrices are able to deliver drug in a time controlled manner, in respect of the poly ethylene oxide molecular weights. The purposes of this work were (i) to study the impact of critical process parameters (extrusion temperature and screw speed) on the drug release behavior, (ii) to determine the impact of formulation parameters (poly ethylene oxide molecular weight, nature of drug and drug loading) on drug release kinetics, and (iii) to evaluate solid dosage forms prepared by hot melt extrusion versus direct compression. Interestingly, the variation of the extrusion temperature and the screw speed leads to the altering of the extrudate appearance and thus the distribution of drug into the extrudate. However, this changing has not influenced the drug release remarkably. Thus, this study was useful to set the parameters for the following projects (temperature 100 °C; screw speed 30 rpm; dosage form size 1 cm). Poly ethylene oxide hot melt extrudates containing 10 % theophylline and based on 100 - 7,000 kDa poly ethylene oxide are used for this thesis. Importantly, the drug release decreased substantially with the increase of the poly ethylene oxide molecular weight from 100 to 600 kDa. However, further increasing of the molecular weights leads to only a slight decrease in the release rate. Swelling studies have shown that this phenomenon correlated with the change in volume of the opaque part of the extrudates (non-transparent gel and solid core).
|
39 |
Desenvolvimento de nanopartículas como sistema carreador para os fungicidas carbendazim e tebuconazole visando aplicações em agricultura / Development of nanoparticles as carrier system for carbendazim and tebuconazole fungicides aiming applications in agricultureCampos, Estefânia Vangelie Ramos, 1989- 02 February 2015 (has links)
Orientador: Leonardo Fernandes Fraceto / Dissertação (mestrado) - Universidade Estadual de Campinas, Instituto de Biologia / Made available in DSpace on 2018-08-26T15:38:39Z (GMT). No. of bitstreams: 1
Campos_EstefaniaVangelieRamos_M.pdf: 7315526 bytes, checksum: e92d25c76302901307a5c47fb9437573 (MD5)
Previous issue date: 2015 / Resumo: O Brasil tornou-se um dos maiores consumidores de defensivos agrícolas em função do seu crescimento no cenário mundial na produção agrícola. Embora esses produtos tragam benefícios para a produção agrícola, têm sido encontrados em concentrações alarmantes nos recursos hídricos e no solo, levando a necessidade de se buscarem alternativas para a redução de seus impactos negativos no meio ambiente. O presente trabalho teve como objetivo o preparo e caracterização de nanopartículas poliméricas (NC) e lipídicas sólidas (NLS) para o carreamento conjunto dos fungicidas carbendazim (MBC) e tebuconazol (TBZ), a fim de aumentar a sua eficácia biológica, além de diminuir os processos físico-químicos de degradação que estes ativos sofrem no ambiente. Os dois sistemas carreadores preparados apresentaram alta eficiência de encapsulação para ambos os fungicidas, superior a 99 %. As NC contendo fungicidas apresentaram diâmetro médio em torno de 550 nm, índice de polidispersão inferior a 0,2 e potencial zeta de aproximadamente -17 mV. Enquanto as NLS apresentaram diâmetro médio em torno de 270 nm, índice de polidispersão superior a 0,2 desde o tempo inicial e potencial zeta de -20 mV. As nanopartículas foram capazes modificar o perfil de liberação dos fungicidas. A liberação do MBC quando associado as nanopartículas em 6 dias foi em torno de 30 % Já para o TBZ no mesmo período de tempo a liberação a partir das nanopartículas foi de 50 %. O modelo matemático que mais se ajustou a liberação do MBC de ambas as nanopartículas foi o de Higuchi. Considerando a liberação do TBZ a partir das nanopartículas o modelo de primeira ordem melhor se ajustou. Os ensaios de liberação em solo demonstrou que as nanopartículas reduzem a porcentagem de lixiviação dos fungicidas, onde para o MBC houve liberação de 17 % a partir da formulação comercial e quando associado as nanopartículas esse valor foi inferior a 5 % com um total de 10 lavagens do solo. Já para o TBZ a formulação comercial liberou 20 % e quando associado as nanopartículas foi em torno de 15 %. Ensaios de viabilidade celular demostraram que as partículas diminuem a toxicidade dos fungicidas à célula animal , sendo os valores de IC50 de 67, 89 e 81 µg/mL para a formulação comercial, NC e SLN respectivamente. Ensaios na espécie P. vulgaris evidenciaram que os fungicidas quando encapsulados causam menos impactos no desenvolvimento das plântulas. Os resultados obtidos mostraram que foi possível preparar sistemas carreadores para os fungicidas sendo, desta forma, obtidos bons sistemas carreadores com modificação no perfil de liberação e diminuição da citotoxicidade, desta forma sendo uma alternativa para o combate de pragas que acometem as culturas na agricultura / Abstract: Brazil has become a major consumer of pesticides according to their growth on the world stage in agricultural production. Although these products bring benefits to agriculture, they cause many impacts to the environment because they are found in high concentrations in soil and water resources. This work aimed to prepare and characterize nanoparticles (polymeric and solid lipid) in order to encapsulate two fungicides carbendazim and tebuconazole. This strategy aims to minimize their impacts to the environment and increase their biological effectiveness, besides of decreasing the physicochemical process of degradation of these compounds into the environment. Both carrier systems showed high encapsulation efficiency for both fungicides (higher than 99 %). The polymeric nanocapsules (NC) with fungicides showed mean diameter around 550 nm, polidispersity lower than 0.2 and zeta potential around - 17 mV. While solid lipid nanoparticles (NLS) showed mean diameter around 270 nm, polidispersity higher than 0.2 since initial time and potential zeta around - 20 mV. Nanoparticles were able to modify the release profile of fungicides. The release of the MBC when associated nanoparticles in 6 days was around 30%. For the TBZ in the same period of time the release from the nanoparticles was 50%. The mathematical model that most adjusted the release of MBC of both nanoparticles was to Higuchi. Whereas the release of the nanoparticles from the TBZ model best fit was observed by the first-order. Cell viability assays showed that particles decrease the toxicity of fungicides, which IC50 values of 67, 89 and 81 µg/mL for the commercial formulation, NC and SLN respectively. The plant assays with P. vulgaris showed that fungicides when encapsulated provoke less impact on seedling development in relation to commercial formulation. The results obtained with these formulations showed that it was possible to prepare nanoparticlescarrier systems for both fungicides in the same carrier and that the fungicide encapsulation decreased the cytotoxicity, increase fungicides effectiveness and thus being a possible alternative to control diseases that affect crops in agriculture / Mestrado / Bioquimica / Mestra em Biologia Funcional e Molecular
|
40 |
Development of 3D printed implants for subcutaneous administration of sustained-release antibodiesCarlier, Emeric 07 July 2021 (has links) (PDF)
Thèse réalisée dans le cadre d'une collaboration avec UCB Pharma et la région Wallonne s'inscrivant dans le cadre du projet SAS. Le but de ce projet était de développer des implants sous-cutanés imprimés en trois dimensions pour permettre une libération d’anticorps thérapeutique de manière prolongée au cours du temps. En effet, les thérapies disponibles sont souvent administrées par voie intraveineuse, ce qui peut réduire la compliance des patients dû à l’inconfort et à la fréquence de ces administrations. Les systèmes de délivrance, tels que des implants, peuvent limiter les fréquences d’administration grâce à l’insertion d’un dispositif qui libèrera le principe actif au cours du temps durant une période donnée. Les implants s’inscrivent comme une alternative aux microsphères qui sont également des dispositifs développés et investigués en vue de favoriser l’adhésion et la compliance des patients. L’avènement du 3D dans le milieu pharmaceutique a montré une certaine frénésie liée au développement de la médecine personnalisée et à l’innovation du procédé dans ce secteur. La sélection d’un matériau biocompatible et biorésorbable tel que le PLGA représente une véritable plus-value dans le développement d’implant. Etant donné que ces implants sont biodégradables, le retrait n’est pas à envisager, ce qui limite les désagréments du patient à un seul acte chirurgical lors de l’implantation. Au cours de ce travail, une approche pragmatique a d’abord été abordée sur les procédés d’extrusion à chaud et de l’impression 3D en utilisant un polymère couramment employé dans l’impression grand public, le PLA. L’investigation des paramètres d’impressions (température d’impression, epaisseur de couche et vitesse d’impression) et l’usage de divers plastifiants (la triacétine (TA), le polyethylène glycol 400 (PEG 400), le citrate de triéthyle (TEC) et l’acétyle citrate de triéthyle (ATEC)) pour faciliter les procédés à chaud et dans l’idée de réduire les températures d’extrusion et d’impression du matériau ont été évalués. Ces essais ont démontré l’effet de la température d’impression sur la qualité de l’impression et principalement sur les propriétés du matériau comme la force de traction et la ductilité. De plus, l’ajout de plastifiant à la matrice du PLA a permis de diminuer sa température de transition vitreuse. Par exemple, la température de transition vitreuse du PLA a été diminuée de 53 °C à 34 °C par l’ajout de PEG 400. Cette approche avait pour but d’évaluer la possibilité de diminuer les températures d’impression dans l’optique d’encapsuler à chaud un anticorps sensible à la chaleur pour la suite de ce travail.Ensuite, le développement de filaments imprimables contenant des anticorps a été abordé et mis en place à l’aide d’un modèle d’anticorps polyclonal disponible en grandes quantités et à des coûts relativement faibles. Un anticorps à l’état solide a été favorisé dans le procédé car il est largement accepté que les protéines sous forme solide sont plus stables au cours du temps en comparaison aux solutions d’anticorps. De plus, cet état solide facilite les manipulations précédant l’extrusion comme l’étape de mélange. Pour la réalisation des filaments, différents types de PLGA ont été investigués afin d’atteindre les propriétés nécessaires à l’impression en termes de diamètre mais également de comportement physique. Ces dérivés étaient caractérisés par des masses moléculaires différentes comme pour le PDLG5004 (44 kDa), le RG502 (7-17 kDa) et parmis eux, un copolymère PEG-PLGA (2 kDa-20 kDa). Un PLGA de faible masse moléculaire a été sélectionné pour développer ce filament. En effet, les extrusions étaient réalisables à une température maximum de 90 °C et les impressions à 113 °C minimum. L’un des enjeux cruciaux du développement de filament imprimable contenant un anticorps à haute concentration, au minimum 15% (w/w), était d’en assurer l’homogénéité. Cependant, l’usage de températures aussi élevées lors de l’impression a induit la dégradation de l’anticorps par la formation d’agrégats et principalement de fragments. Ces derniers sont généralement produits lors de procédé à haute température ou par l’usage de conditions drastiques telles que l’acidification du milieu. Cette plateforme a été adaptée à l’encapsulation d’anticorps thérapeutique fournit par UCB Pharma. L’usage d’un anticorps monoclonal possédant une stabilité supérieure à celle du modèle initialement utilisé permettrait d’identifier l’impact du procédé sur l’intégrité de l’anticorps. La formulation de l’anticorps a été réalisée en utilisant différents stabilisants conventionnels (sucrose (Suc), trehalose (Tre), 2-Hydroxypropyl-beta-cyclodextrine (HP-β-CD), inuline (Inu) et sorbitol (Sor)) et reconnus pour la stabilisation des protéines. A côté des excipients ajoutés, différentes quantités d’excipients ont été investigués. Ces manipulations ont montré que la stabilité de l’anticorps était privilégiée à l’aide du sucrose et du tréhalose à un ratio anticorps monoclonal:excipient de 2.0:1. En gardant ce ratio, l’ajout d’un acide aminé (leucine) aux deux disaccharides précédemment cités, a amélioré la stabilité de l’anticorps vis-à-vis des procédés à chaud (extrusion et impression 3D). L’homogénéité au sein des filaments imprimables et des pièces 3D a été confirmée tout au long du procédé. En effet, les charges en anticorps étaient similaires à la charge théorique de 15% (w/w). Aucune fragmentation de l’anticorps n’a été observée à l’issue des procédés à chaud. Cependant, une augmentation des agrégats de 2.6% en solution à 3.6% après impression 3D a été constatée à la fin du processus. Après avoir stabilisé l’anticorps, le but premier étant d’en promouvoir une libération prolongée au cours du temps. Les profils ont révélé une libération en trois phases au cours du temps mais avec un relargage après 24h relativement faible (< 5%) dû à la densité des matrices polymériques. Ensuite, la dégradation du polymère représente l’élément limitant la libération de l’anticorps au cours du temps. En effet, l’érosion du polymère joue un rôle clé dans la libération de l’anticorps encapsulé. La libération au cours du temps a été démontrée sur une période allant jusqu’à 15 semaines. La stabilité de l’anticorps dans le milieu de dissolution a été évaluée et une dégradation de celui-ci au cours du temps a été observée. Cette dégradation est principalement liée à l’érosion du polymère et à l’acidification du milieu au cours du test de dissolution. Après avoir optimisé la formulation de l’anticorps et avoir démontré la libération prolongée de celui-ci, son affinité restait à être étudiée. La capacité de l’anticorps à se lier à sa cible a pu être démontrée après 24h de dissolution mais cette affinité s’est réduite au cours de la durée de la dissolution avec une augmentation de l’agrégation et de la fragmentation de l’anticorps. Une étude de stabilité a également démontré que les implants imprimés en 3D sont stables à une température 5 °C sur une durée de 6 mois. Aucun élément de dégradation n’a été observé au cours du temps et l’affinité de l’anticorps a été préservée au cours de l’étude. Finalement, cette plateforme a également été évaluée pour l’encapsulation d’une troisième molécule biologique, un fragment d’anticorps monoclonal, pour d’une part en estimer la stabilité et l’applicabilité et d’autre part envisager une prochaine étude pré-clinique sur rongeurs. Le fragment d’anticorps a montré une stabilité supérieure à celle de l’anticorps monoclonal avec une faible agrégation après l’extrusion et l’impression. La libération prolongée du fragment a été évaluée sur 8 semaines et une libération du fragment de 79% a été observée avec une formulation contenant du tréhalose et de la leucine. En effet, les fragments d’anticorps ont une demi-vie plasmatique relativement faible, de l’ordre de 28 minutes, ce qui donne tout son sens à des systèmes à libération prolongée. Pour finir, la réalisation d’une étude pré-clinique permettrait de valider le modèle. En conclusion, ce travail a démontré la faisabilité de l’usage de l’impression 3D en vue de développer des systèmes à libération prolongée contenant des anticorps et en utilisant des procédés à hautes températures. Ces implants ont été caractérisés par une stabilité favorable et une libération intéressante qui feront l’objet d’investigation lors d’études pharmacocinétiques. / Doctorat en Sciences biomédicales et pharmaceutiques (Pharmacie) / info:eu-repo/semantics/nonPublished
|
Page generated in 0.0962 seconds